Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 21Recruiting 5Terminated 4Unknown 3Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 65NIH 18UNKNOWN 6OTHER_GOV 3INDUSTRY 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Sarcoma 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Epirubicin × Clear all
NCT04490993 2022-02-22

ACCRUE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
359 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04736394 2022-02-22

ASCERTAIN

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
800 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05121350 2022-02-18

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
256 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡